期刊文献+

18F-FDGPET-CT及其他临床病理因素对套细胞淋巴瘤预后的预测价值 被引量:2

Prognostic value of ^(18)F-fluoro-deoxyglucose positron emission tomography-computed tomography and some clinicopathological factors for mantle cell lymphoma
原文传递
导出
摘要 目的 :探讨氟代脱氧葡萄糖正电子发射体层摄影术-计算机体层摄影术(18F-l uoro-deoxyglucose positron emission tomography-computed tomography,18F-FDG PET-CT)及其他临床病理因素对套细胞淋巴瘤(mantle cell lymphoma,MCL)预后的预测价值。方法 :回顾性分析2009年2月—2012年11月在北京大学肿瘤医院接受诊治的19例初治MCL患者的病历资料和随访资料,分析18F-FDG PET-CT及其他临床病理因素与MCL无进展生存(progression-free survival,PFS)和总生存(overall survival,OS)的关系。结果 :17例患者接受分期评估时的18F-FDG PET-CT均显示代谢增加,中位最大标准摄取值(maximum standardized uptake value,SUVmax)为7.4(范围:2.5~18.3)。在有骨髓侵犯的8例患者中,仅2例的18F-FDG PET-CT提示骨髓侵犯。18F-FDG PETCT的SUVmax与Ki-67(Ki-67≥30%vs<30%)无关(P>0.05)。中位随访时间为29个月(范围:3~58个月),估算3年OS率为71%,3年PFS率为74%。单因素分析显示,Ki-67和疗效与PFS(P=0.000、P=0.004)和OS(P=0.002、P=0.004)均明显相关,而国际预后指数(International Prognostic Index,IPI)、简化MCL国际预后指数(simplii ed MCL International Prognostic Index,sMIPI)和分期评估18F-FDG PET-CT的SUVmax均与PFS和OS无明显相关性(P>0.05)。COX比例风险回归模型分析显示,Ki-67、IPI、sMIPI、分期评估18F-FDG PET-CT的SUVmax和疗效均对预后无明显影响(P>0.05)。结论 :18F-FDG PET-CT作为MCL的检查手段之一,对骨髓侵犯的检出率较低。Ki-67和疗效可能与MCL患者的预后相关,但仍待大样本临床试验予以验证。 Objective: To investigate the prognostic value of 18F-fluoro-deoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) and some clinicopathological factors for mantle cell lymphoma (MCL). Methods: Clinical records and follow-up information of 19 untreated patients with MCL admitted in Peking University Cancer Hosipital between February 2009 and November 2012 were reviewed. The impacts of 18F-FDG PET-CT and some clinicopathological factors on progression-free survival (PFS) and overall survival (OS) were evaluated. Results: Seventeen patients had an 18F-FDG PET-CT with an abnormal uptake value [the median maximum standardized uptake value (SUVmax) was 7.4 (range: 2.5-18.3). Bone marrow (BM) biopsies demonstrated disease in 8 patinets, but only 2 of them had 18F-FDG uptakes. There was no statistically significant relationship between SUVmax and Ki-67 (≥30% vs 〈 30%). The median follow-up time was 29 months (range: 3-58) with an estimated 3-year PFS of 74% and an estimated 3-year OS of 71%. Univariate analysis showed that Ki-67 and response were associated with PFS (P = 0.000; P = 0.004) and OS (P = 0.002; P = 0.004), but International Prognostic Index (IPI), simplified MCL International Prognostic Index (sMIPI) and initial ~SF-FDG PET-CT SUVmax were not associated with PFS and OS (P 〉 0.05). COX proportional-hazards regression model revealed that Ki-67, IPI, sMiPI, initial 18F-FDG PET-CT SUVmax and response were not associated with PFS and OS (P 〉 0.05). Conclusion: 18F-FDG PET-CT at diagnosis is complementary to conventional evaluations, but BM biopsies remain mandatory. More large-sample clinical trials may be needed to further verify the association of Ki-67 and response with the prognosis of MCL.
出处 《肿瘤》 CAS CSCD 北大核心 2014年第6期536-540,共5页 Tumor
关键词 非霍奇金淋巴瘤 套细胞淋巴瘤 18F-FDG PET-CT 预后 Non-Hodgkin's lymphoma Mantle cell lymphoma 18F-FDG PET-CT Prognosis
  • 相关文献

参考文献14

  • 1Sun J, Yang Q, Lu Z, et al.Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification[J]. Am J Clin Pathol, 201 2, 138(3):429-434.
  • 2Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma[J]. J Clin Oncol, 2009, 27(4):511-518.
  • 3Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma[J]. Blood, 2008, 111(2):558-565.
  • 4Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD[J]. Blood, 2008, 112(6):2583-2584.
  • 5Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group[J]. Blood, 2008, 111 (4):2385-2387.
  • 6Meignan M, Barrington S, Itti E, et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012[J]. Leuk Lymphoma, 2014, 55(1 ):31-37.
  • 7A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project[J]. N EnglJ Med, 1993,329(14):987-994.
  • 8Todorovic M, Balint B, Andjelic B, et al. Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study[J]. Med Oncol, 2012, 29(3):2212-2219.
  • 9阎骅,沈志祥.淋巴瘤循证治疗解读[J].肿瘤,2008,28(9):733-735. 被引量:4
  • 10Brepoels L, Stroobants S, De Wever W, et al. Positron emission tomography in mantle cell lymphoma[J]. Leuk Lymphoma, 2008, 49(9):1693-1701.

二级参考文献10

  • 1FISHER R I, GAYNOR E R, DAHLBERG S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin' s lymphoma [ J ]. N Engl J Med, 1993, 328 ( 14 ) : 1002-1006.
  • 2COIFFER B, HAIOUN C, KETTERIER N, et al. Rituximab anti- CD20 monoclonal antihody for the treatment of patients with relapsing of refractory aggressive lymphoma. A multicenter phase Ⅱ study[J]. Blood, 1998, 92(6) :1927-1932.
  • 3VOSE J M, LINK B K, GROSSBARD M L, et al. Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hudgkin' s lymphoma [J]. J Clin Oncol, 2001, 19(2):389-397.
  • 4FEUGIER P, VAN HOOF A, SEBBAN C, et al. Long-term resuits of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Grouped' Etude des Lymphomas des' Adulte [ J ]. J Clin Oncol, 2005, 23 ( 18 ) :4117- 4-126.
  • 5HABERMANN T M, WELLER E A ,MORRISON V A ,et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma [ J ]. J Clin Oncol, 2006, 24(19) :3121-3127.
  • 6PFREUNDSCHUH M. TRUMPER L, OSTERBORG A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MinT) Group[ J ]. Lancet Oncol, 2006, 7 (5) : 379-391.
  • 7PFREUNDSCHUH M,SCHUBERT J.ZIEPERT M,et al. Six versus eight cycles of hi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 ^+ B-cell lymphomas: a randomized controlled trial ( RICOVER-60 ) [ J ]. Lancet Oncol, 2008, 9(2) :105-116.
  • 8HUTCHING M,SPECHT L. PET/CT in the management of hematological malignancies[J].Eur J Haematol, 2008, 80 ( 5 ) : 369- 380.
  • 9PELOSI E, PREGNO P, PENNA D, et al. Role of whole-body [ (18) F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma[ J ]. Radiol Med(Torino) , 2008, 14 [ Epub ahead of print ].
  • 10KWEE TC, KWEE RM, NIEVELSTEIN RA. Imaging in staging of malignant lymphoma: a systematic review [ J ]. Blood, 2008, I 11 (2) :504-516.

共引文献3

同被引文献12

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部